Ieq Capital LLC Increases Stake in Abbott Laboratories $ABT

Key Points

• Ieq Capital LLC increased its holdings in Abbott Laboratories by 4.9%, now owning 141,624 shares valued at approximately $18.8 million.
• Abbott Laboratories reported earnings of $1.26 EPS for the last quarter, meeting analyst expectations, with a revenue of $11.14 billion.
• The company declared a quarterly dividend of $0.59, representing an annualized dividend of $2.36 and a yield of 1.8%.

Ieq Capital LLC increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 4.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 141,624 shares of the healthcare product maker's stock after acquiring an additional 6,564 shares during the quarter. Ieq Capital LLC's holdings in Abbott Laboratories were worth $18,786,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Kelly Financial Services LLC purchased a new stake in Abbott Laboratories in the 1st quarter worth approximately $216,000. Voleon Capital Management LP bought a new position in Abbott Laboratories in the 4th quarter worth approximately $273,000. Bank Pictet & Cie Europe AG boosted its stake in Abbott Laboratories by 1.9% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after purchasing an additional 2,774 shares during the period. Edge Financial Advisors LLC boosted its stake in Abbott Laboratories by 3.3% in the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after purchasing an additional 81 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in Abbott Laboratories by 6.5% in the 4th quarter. Ameriprise Financial Inc. now owns 12,865,656 shares of the healthcare product maker's stock worth $1,451,032,000 after purchasing an additional 781,264 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded up $1.22 during midday trading on Friday, reaching $132.59. 4,430,637 shares of the stock traded hands, compared to its average volume of 5,397,552. The company's 50 day moving average is $130.99 and its 200 day moving average is $131.35. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The stock has a market capitalization of $230.76 billion, a PE ratio of 16.61, a P/E/G ratio of 2.52 and a beta of 0.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the firm posted $1.14 EPS. Abbott Laboratories's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date was Tuesday, July 15th. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ABT has been the subject of several recent analyst reports. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Mizuho upped their price target on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 16th. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and upped their price target for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. BTIG Research dropped their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research note on Friday, July 18th. Finally, Raymond James Financial lowered their target price on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.